AngioDynamics (NASDAQ:ANGO) released its quarterly earnings results on Wednesday. The medical instruments supplier reported $0.25 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.26 by ($0.01), Morningstar.com reports. The firm had revenue of $96.30 million for the quarter, compared to analyst estimates of $92.34 million. AngioDynamics had a net margin of 17.06% and a return on equity of 5.58%. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.20 EPS. AngioDynamics updated its FY 2020 guidance to $0.25-0.30 EPS and its FY20 guidance to $0.25-0.30 EPS.
Shares of NASDAQ ANGO opened at $21.68 on Friday. The firm has a 50-day moving average of $19.62. AngioDynamics has a 52-week low of $18.11 and a 52-week high of $25.48. The firm has a market capitalization of $814.66 million, a price-to-earnings ratio of 26.69 and a beta of 0.69. The company has a current ratio of 4.30, a quick ratio of 1.70 and a debt-to-equity ratio of 0.20.
Several analysts recently commented on the stock. BidaskClub upgraded shares of Westport Fuel Systems from a “hold” rating to a “buy” rating in a research report on Friday. Zacks Investment Research upgraded shares of Investar from a “hold” rating to a “buy” rating and set a $27.00 target price on the stock in a research report on Tuesday, June 4th. TheStreet lowered shares of Upland Software from a “b-” rating to a “c+” rating in a research report on Wednesday. Finally, ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $21.50.
Several hedge funds and other institutional investors have recently made changes to their positions in ANGO. Victory Capital Management Inc. grew its position in shares of AngioDynamics by 38.3% in the first quarter. Victory Capital Management Inc. now owns 2,686,696 shares of the medical instruments supplier’s stock valued at $61,418,000 after purchasing an additional 744,085 shares during the period. Tributary Capital Management LLC grew its position in shares of AngioDynamics by 39.9% in the first quarter. Tributary Capital Management LLC now owns 704,499 shares of the medical instruments supplier’s stock valued at $16,105,000 after purchasing an additional 200,829 shares during the period. Segall Bryant & Hamill LLC grew its position in shares of AngioDynamics by 19.2% in the fourth quarter. Segall Bryant & Hamill LLC now owns 1,136,657 shares of the medical instruments supplier’s stock valued at $22,881,000 after purchasing an additional 183,368 shares during the period. BlackRock Inc. grew its position in shares of AngioDynamics by 2.8% in the fourth quarter. BlackRock Inc. now owns 5,918,221 shares of the medical instruments supplier’s stock valued at $119,134,000 after purchasing an additional 158,932 shares during the period. Finally, Penn Capital Management Co. Inc. acquired a new stake in shares of AngioDynamics in the fourth quarter valued at about $2,057,000. Institutional investors and hedge funds own 98.46% of the company’s stock.
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Further Reading: Are analyst ratings accurate?
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.